parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.05 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in hofbauer cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	3 Parkinson's trials, 0 stopped	1.00
literature PubMed	17 Parkinson's papers of 3,984	0.62
pathways Reactome	3 pathways; mostly immune signalling	0.90

No case: the score is under the bar. Receipt 4816

receipt 4854: CCL3 in dopamine neurons, braak

power: full sample -0.14 (p 0.579, n 18), 95% CI -0.57 to +0.35. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.16 (p 0.538, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.555, n 18). could be the mix.
skeptic: leave-one-out range -0.25 to -0.02, sign flips 0; without severely affected donors -0.14 (p 0.579, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CCL3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4853: CCL3 in microglia, braak

power: full sample -0.32 (p 0.190, n 18), 95% CI -0.69 to +0.17. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.29 (p 0.249, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.06 (p 0.807, n 18). could be the mix.
skeptic: leave-one-out range -0.47 to -0.25, sign flips 0; without severely affected donors -0.32 (p 0.190, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CCL3 in microglia.

case closed: nothing better to follow up.

loading the receipts